Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites Clinical Trial

Official title:

A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites (OPTIONS-02)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05303844
• Other study ID #: 2201249-7
• Status: Recruiting
• Phase: Phase 1
• Start date: April 2, 2022
• Est. completion date: March 20, 2025

Study information

• Verified date: April 2023
• Source: Fudan University
• Contact: Peng Wang, MD
• Phone: 86-21-64175590
• Email: peng_wang[@]fudan.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.

Description:

This study is to evaluate the safety, effectiveness of local immune activation, and efficiency in patients with refractory malignant ascites after Intraperitoneal injection of oncolytic Viruses H101 and Tislelizumab.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: March 20, 2025
• Est. primary completion date: March 20, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent obtained.

• Age = 18 years at time of study entry.

• Pathologically diagnosed solid tumor malignancy.

• Malignant peritoneal ascites confirmed by peritoneal brush cytology.

• Failures from chemotherapy against malignant ascites.

• Cooperative Oncology Group-Status (ECOG Status) 0 or 1

Exclusion Criteria:

• Previous (<4 weeks) or concurrent treatment with systemic or intraperitoneal chemotherapy or biological agents such as monoclonal antibodies.

• History of cardiac disease, including clinically significant gastrointestinal bleeding within 4 weeks prior to start of study treatment

• Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months Prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.

• Prior treatment with oncolytic virotherapy.

• Radiotherapy administered less then 4 weeks prior to study treatment start.

• Major surgery within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery.

• Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix.

• Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV).

• Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is longer.

• Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study Treatment or interpretation of patient safety or study results, including but not limited to:

• history of interstitial lung disease

• Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) coinfection (i.e double infection)

• known acute or chronic pancreatitis

• active tuberculosis

• any other active infection (viral, fungal or bacterial) requiring systemic therapy

• history of allogeneic tissue/solid organ transplant

• diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of Tislelizumab treatment.

• Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions: Subjects with vitiligo, hypothyroidism, diabetes mellitus type I or resolved childhood asthma/atopy are an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with Hashimoto thyroiditis, hypothyroidism stable on hormone replacement or psoriasis not requiring treatment are not excluded from the study.

• Live vaccine within 30 days prior to the first dose of Tislelizumab treatment or during study treatment.

• History or clinical evidence of Central Nervous System (CNS) metastases Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria: I. are asymptomatic and II. have no requirement for steroids 6 weeks prior to start of Tislelizumab treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS

• Medication that is known to interfere with any of the agents applied in the trial.

• Any other efficacious cancer treatment except protocol specified treatment at study start.

• Patient has received any other investigational product within 28 days of study entry.

• Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum ß-HCG) at screening.

Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

Related Conditions & MeSH terms

• Ascites
• Refractory Malignant Ascites

Intervention

Drug:
• H101
H101 intratumorally injection starts at day 0.
• Tislelizumab
Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patient with dose-limiting toxicities (DLTs) as evaluated accordingly to CTCAE 5.0	The DLT assessment period is defined as: Day of Injection through 28 days post injection (Safety Follow Up). A DLT will be defined as any Grade 3 or higher adverse event, as assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.	28 days
Primary	Maximum tolerated dose (MTD) of intratumoral injection of H101 on at three dose levels in combination with anti-PD1 antibody.	A MTD is determined if any cohort experiences 2 subjects with DLT's.	28 days
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0		max 24 months
Secondary	Ascites Objective Response Rate	The ascites objective response rate (ORR) was calculated as a summed ratio of patients with disappeared and decreased ascites to the total number of patients.	max 24 months
Secondary	Objective Response Rate (ORR)	ORR according to RECIST 1.1	max 24 months
Secondary	Duration of Response		max 24 months
Secondary	Progression Free Survival		max 24 months
Secondary	Overall survival		max 42 months
Secondary	disease control rate		max 24 months
Secondary	Change from baseline local immune effects after H101 intraperitoneal injections	Detection of increased local immune activation in malignant ascites will be assessed by single cell sequencing and/or Mass Cytometry (CyTOF).	max 24 months